All In Biotech

NDA 021621 · Kenvue Brands

Children'S Zyrtec Allergy

Cetirizine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Mar 16, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

134

35 Phase 3, 7 recruiting

FAERS reports

125,869

60,579 serious, 7,591 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 27, 2026.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 16, 2007 Supplement 5 · Efficacy LetterReview
  • Mar 16, 2004 Original approval · Type 3 - New Dosage Form LetterReview
5 products under this application
  • CHILDREN'S ZYRTEC ALLERGY · CETIRIZINE HYDROCHLORIDE 2.5MG · TABLET, CHEWABLE, ORAL · Over-the-counter
  • CHILDREN'S ZYRTEC HIVES RELIEF · CETIRIZINE HYDROCHLORIDE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, CHEWABLE, ORAL · Discontinued
  • CHILDREN'S ZYRTEC ALLERGY · CETIRIZINE HYDROCHLORIDE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, CHEWABLE, ORAL · Discontinued
  • CHILDREN'S ZYRTEC HIVES RELIEF · CETIRIZINE HYDROCHLORIDE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, CHEWABLE, ORAL · Discontinued
  • CHILDREN'S ZYRTEC ALLERGY · CETIRIZINE HYDROCHLORIDE 10MG · TABLET, CHEWABLE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetirizine" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective18,075
  • fatigue14,947
  • pain12,772
  • off label use11,291
  • headache10,290
  • rash10,192
  • pruritus9,539
  • nausea9,229
  • alopecia8,700
  • abdominal discomfort8,632
  • dyspnoea7,961
  • rheumatoid arthritis7,897

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,241
20051,289
20061,241
20071,193
20081,333
20091,392
20101,867
20111,929
20122,524
20132,497
20143,141
20157,785
20168,477
20177,306
20187,362
20197,799
20208,608
20219,966
202210,533
20239,540
202410,389
202510,425
20268,025

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 531 on PubMed

Sponsor: Kenvue Brands · Also marketed as Children'S Zyrtec Hives Relief

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.